Followers | 17 |
Posts | 2065 |
Boards Moderated | 1 |
Alias Born | 09/27/2020 |
Friday, June 16, 2023 8:25:34 PM
A whole bunch of ass kissing going on in that exchange between "analyst" and CEO. Nauseating, actually. I wonder how much this person invested in this company, or how much he convinced others to invest. I bet it was in the six figures given the likelihood they felt they had the CEO's ear and certainly the inside scoop on what was going on at Amarantus Bioscience.
Amarantus was a penny stock after all, and every reputable analyst will tell you they are high risk/high reward and to invest only what you're comfortable losing. Things don't always work out as planned or intended, and one has to account for that. Small companies are extremely risky because of limited capital and limited options to raise capital, options that are readily available to larger, established companies. A couple of failed ventures may sink a small OTC company, while larger companies take it in stride because of success in other areas. Investors who don't understand the risks, who dream of wealth, and who are likely to invest so much they become angry and bitter if faced with losses, should probably stick to mutual funds or listed companies.
I wonder what ever happened to this "analyst"... did their zip code change for the better? Are they still great pals with the CEO? Did they have a personal "Come to Jesus" call with the CEO? Did that cause them to invest even more money? Did they follow the CEO to their next company and invest there? What are they up to today? Did they move to a reputable investment advisory firm, or are they still poking around in risky penny stock investments? Anyone know?
Asking for a friend.
Avant Technologies and Ainnova Tech Form Joint Venture to Advance Early Disease Detection Using Artificial Intelligence • AVAI • Nov 12, 2024 9:00 AM
Swifty Global Announces Launch of Swifty Sports IE, Expanding Sports Betting and Casino Services in the Irish Market • DRCR • Nov 12, 2024 9:00 AM
Oohvie App Update Enhances Women's Health with Telemedicine and Online Scheduling • HLYK • Nov 11, 2024 8:00 AM
SANUWAVE Announces Record Quarterly Revenues: Q3 FY2024 Financial Results • SNWV • Nov 8, 2024 7:07 AM
DBG Pays Off $1.3 Million in Convertible Notes, which Retires All of the Company's Convertible Notes • DBGI • Nov 7, 2024 2:16 PM
SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • SMX • Nov 7, 2024 8:48 AM